Summary
Danaher Corporation reported robust growth in its 2011 fiscal year, driven by strong performance across its diverse segments, particularly the Life Sciences & Diagnostics division, which was significantly bolstered by the acquisition of Beckman Coulter. The company's strategic focus on the Danaher Business System (DBS) continues to be a key driver of operational efficiency and value creation. Danaher maintained a strong financial position, evidenced by healthy operating cash flow and a diverse revenue stream across its five reportable segments: Test & Measurement, Environmental, Life Sciences & Diagnostics, Dental, and Industrial Technologies. The company's acquisition strategy remains active, with continued investment in businesses that align with its strategic goals and enhance its market positions, alongside the divestiture of non-core assets. Looking ahead, Danaher anticipates continued sales growth from existing businesses, albeit at a moderating pace, supported by ongoing investments in innovation and market expansion, particularly in emerging markets. The integration of Beckman Coulter is expected to yield significant synergies and contribute to future growth. The company's financial health is supported by a well-managed debt structure and ample liquidity, positioning it to pursue strategic opportunities while navigating the evolving economic landscape.
Financial Highlights
52 data points| Revenue | $16.09B |
| Cost of Revenue | $7.91B |
| Gross Profit | $8.18B |
| R&D Expenses | $1.02B |
| SG&A Expenses | $4.61B |
| Operating Income | $2.62B |
| Interest Expense | $141.60M |
| Net Income | $2.17B |
| EPS (Basic) | $3.21 |
| EPS (Diluted) | $3.11 |
| Shares Outstanding (Basic) | 676.20M |
| Shares Outstanding (Diluted) | 701.20M |
Key Highlights
- 1Danaher Corporation experienced significant sales growth in 2011, driven by both organic growth (7.0%) and strategic acquisitions, with the Life Sciences & Diagnostics segment showing substantial expansion.
- 2The acquisition of Beckman Coulter, Inc. for approximately $5.5 billion was a major event, significantly expanding Danaher's presence in clinical diagnostics and life sciences research.
- 3The company generated strong operating cash flow, indicating operational efficiency and financial health, supporting its ability to invest in growth and manage its capital structure.
- 4Danaher continued to invest in research and development, with R&D expenses increasing to $1.02 billion, reflecting a commitment to innovation across its product lines.
- 5The company strategically divested certain non-core assets, including the Pacific Scientific Aerospace business, to streamline operations and focus on core growth areas.
- 6Danaher's diversified business model, spanning five segments (Test & Measurement, Environmental, Life Sciences & Diagnostics, Dental, Industrial Technologies), provided resilience and broad market exposure.
- 7The Danaher Business System (DBS) continues to be central to the company's strategy for driving continuous improvement in quality, delivery, cost, and innovation.